Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease
- 2 July 2010
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 58 (7), 1311-1317
- https://doi.org/10.1111/j.1532-5415.2010.02906.x
Abstract
OBJECTIVES: To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) ɛ4 allele. DESIGN: A cohort of cognitively intact elderly participants was assessed biennially for dementia and AD. SETTING: Community based. PARTICIPANTS: Three thousand three hundred ninety‐two members of a health maintenance organization (HMO) aged 65 and older and without dementia. MEASUREMENTS: Statin use was identified from the HMO pharmacy database, and proportional hazards models were applied with statin use as a time‐dependent covariate to assess the association between statins and AD and the modifying effects of age and the APOE ɛ4 allele. RESULTS: Over an average of 6.1 years of follow‐up of 3,099 participants, 263 participants developed probable AD. The adjusted hazard ratio (aHR) for statin use was 0.62 (95% confidence interval (CI)=0.40–0.97) for AD in models including demographic characteristics and vascular risk factors as covariates. The strength of the association between statins and AD diminished with age (statin‐by–age at entry interaction P=.04); the aHR in those younger than 80 was 0.44 (95% CI=0.25–0.78), versus 1.22 (95% CI=0.61–2.42) for aged 80 and older. The interaction term for statin use–by–APOE ɛ4 was not significant (P=.65). CONCLUSION: This enlarged study confirms earlier findings that statin therapy in early old age, but not in late age, may be associated with a lower risk of AD. The relationship between statin use and AD was consistent across APOE genotypes.Keywords
This publication has 25 references indexed in Scilit:
- Vascular Care in Patients with Alzheimer's Disease with Cerebrovascular Lesions—A Randomized Clinical TrialJournal of the American Geriatrics Society, 2009
- Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam StudyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort studyNeurology, 2008
- Statin therapy is associated with reduced neuropathologic changes of Alzheimer diseaseNeurology, 2007
- Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trialAnnals of Neurology, 2002
- The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial InfarctionCirculation, 2000
- TIME-DEPENDENT COVARIATES IN THE COX PROPORTIONAL-HAZARDS REGRESSION MODELAnnual Review of Public Health, 1999
- The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of DementiaInternational Psychogeriatrics, 1994
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984